Arthritis News and Research

Latest Arthritis News and Research

La Jolla Institute for Allergy & Immunology awarded $18.8M NIH grant for infectious diseases study

Researchers from the La Jolla Institute for Allergy & Immunology will take aim at several of the world's most dangerous infectious diseases - tuberculosis, malaria and dengue virus -- in a five-year, $18.8 million federally-funded set of projects seeking to make new inroads toward vaccines against the disorders.

17 Dec 2009

ASA offers practical ways for sufferers to take active role in treatment of pain

Whether the result of injury, illness or a chronic condition, 70 million Americans experience pain annually. The individual pain sufferer may experience a diminished quality of life, lack of mobility and added stress.

17 Dec 2009

Forest Laboratories Holdings and Almirall to develop, market and distribute LAS100977 in the US

Forest Laboratories Holdings, Ltd., a wholly owned subsidiary of Forest Laboratories, Inc. and Almirall, S.A. (ALM.MC) today announced that they have entered an agreement to develop, market and distribute LAS100977 in the United States.

17 Dec 2009

People are more prone to Crohn's disease and ulcerative colitis, explains new research

New research by the University of Adelaide could help explain why some people are more prone to Crohn's disease, ulcerative colitis and other autoimmune diseases.

17 Dec 2009

Top-line efficacy and safety results from Phase 2b clinical trial of XIAFLEX announced

BioSpecifics Technologies Corp., a biopharmaceutical company developing first in class collagenase-based products, today announced top-line efficacy and safety results from a Phase 2b clinical trial of XIAFLEX(TM) for the treatment of Peyronie's disease.

17 Dec 2009

ChemoCentryx commences enrollment in CCX354 Phase 2 clinical trial for RA

ChemoCentryx, Inc. today announced that it has begun enrolling patients in a Phase 2 clinical trial of CCX354, an orally-bioavailable, novel, small molecule drug designed to specifically target the CCR1 chemokine receptor for the treatment of rheumatoid arthritis (RA).

16 Dec 2009

Femta Pharmaceuticals, Lonza Group collaborate in cGMP production of FM101 antibody

Femta Pharmaceuticals and Lonza Group Ltd jointly announce the execution of a manufacturing services agreement to facilitate the development and cGMP manufacturing of FM101. FM101 is a high affinity monoclonal antibody in late pre-clinical development for the treatment of Rheumatoid Arthritis.

15 Dec 2009

Celgene announces positive data from its apremilast Phase IIb study for plaque-type psoriasis

Celgene Corporation announced clinical data from an investigational Phase IIb, double-blind, placebo-controlled study of apremilast (CC-10004) in patients with moderate-to-severe plaque-type psoriasis (PSOR-005). This was a 352-patient, multi-center study in which patients received either 10mg, 20mg or 30mg of apremilast twice per day (BID), or placebo.

15 Dec 2009

Medicare power mobility remains a viable option for beneficiaries

Across America, seniors, together with their families and caregivers, are making difficult decisions about the future. Did that last emergency room visit after a fall mean it's time to consider nursing homes? How much longer can their loved one remain safely in their own home or apartment?

15 Dec 2009

Celebrex stops aspirin from doing its job effectively

Millions of Americans take Celebrex for arthritis or other pain. Many, if they are middle-aged or older, also take a low-dose aspirin tablet daily to reduce the risk of heart attack and stroke. Yet they may be getting little protection, because Celebrex keeps the aspirin from doing its job effectively, a new study suggests.

15 Dec 2009

Amgen receives worldwide rights to Array’s small-molecule glucokinase activator program

Array BioPharma Inc. and Amgen Inc.(NASDAQ: AMGN) today announced that they entered into an agreement granting Amgen exclusive worldwide rights to Array’s small-molecule glucokinase activator program, including ARRY-403, currently being tested in a Phase 1 clinical trial in patients with Type 2 diabetes.

14 Dec 2009

UCB offers tips for managing rheumatoid arthritis during festive season

A third of women living with rheumatoid arthritis say their disease impacts their enjoyment of the festive season - Women living with rheumatoid arthritis find shopping for gifts, preparing holiday food, writing cards and wrapping presents most difficult to do - Nearly two thirds of women living with rheumatoid arthritis experience pain daily

14 Dec 2009

NICE guidelines limit options for low cost osteoporosis drugs

Low cost osteoporosis drugs are strictly rationed for the under 75s, and UK physicians hampered by restrictive guidelines, according to findings which appear today in the journal Therapeutic Advances in Musculoskeletal Disease, published by SAGE.

14 Dec 2009

Disabilities account for a quarter of U.S. adult health care costs

"Just over one-quarter of U.S. adult health care spending was associated with disability in 2006, according to a new study by researchers at RTI International and the U.S. Centers for Disease Control & Prevention," Insurance Journal reports.

11 Dec 2009

Hot Ideas World creates Eye-POD Eye Care Kit

The Eye-POD Eye Care Kit has just been created by an entrepreneurial R&D company in Florida, Hot Ideas World, Inc. The array of easy to use functions in the device changes the way users wear Contact Lenses and use Eye Drops.

11 Dec 2009

Oconomowoc Memorial Hospital performs partial knee resurfacing surgery using MAKOplasty technology

For the first time in Wisconsin, patients suffering from arthritis pain have access to a new procedure that uses the precision of robotics to perform partial knee resurfacing surgery. The technology, called MAKOplasty®, is a minimally invasive surgical option that results in shorter hospital stays and faster healing than traditional knee surgeries.

11 Dec 2009

Genentech and Biogen Idec report positive outcome from ocrelizumab-MTX combination study in RA

Genentech, Inc. a wholly owned member of the Roche Group, and Biogen Idec announced today a Phase III study (STAGE) of the investigational humanized anti-CD20 monoclonal antibody ocrelizumab given in combination with methotrexate (MTX) met its primary endpoint of improving signs and symptoms (as measured by American College of Rheumatology or ACR20 response) in rheumatoid arthritis (RA) patients who had an inadequate response to MTX at both 24 and 48 weeks.

11 Dec 2009

Nutritional supplements to strengthen immunity and improve periodontal health

The PA periodontists in Dr. David DiGiallorenzo's Collegeville and Williamsport practice recently began offering two lines of nutritional supplements to patients as a means of promoting the connection between good nutrition and improved periodontal health.

11 Dec 2009

Scientists develop new model of skin cancer based on Src kinases

Scientists at the University of Pennsylvania School of Medicine have developed a new model of skin cancer based on the knowledge that a common cancer-related molecule called Src kinase is activated in human skin-cancer samples.

11 Dec 2009

Fulvestrant 500 mg reduces risk of disease progression in women with metastatic breast cancer

AstraZeneca (NYSE: AZN) today announced that data from a Phase III study of postmenopausal women with hormone receptor-positive advanced breast cancer presented at the San Antonio Breast Cancer Symposium (Abstract 25) showed treatment with fulvestrant (FASLODEX) 500 mg reduced the risk of disease progression (assessed as time to progression (TTP)) by 20%

11 Dec 2009

Arthritis News and Research

Latest Arthritis News and Research

La Jolla Institute for Allergy & Immunology awarded $18.8M NIH grant for infectious diseases study

ASA offers practical ways for sufferers to take active role in treatment of pain

Forest Laboratories Holdings and Almirall to develop, market and distribute LAS100977 in the US

People are more prone to Crohn's disease and ulcerative colitis, explains new research

Top-line efficacy and safety results from Phase 2b clinical trial of XIAFLEX announced

ChemoCentryx commences enrollment in CCX354 Phase 2 clinical trial for RA

Femta Pharmaceuticals, Lonza Group collaborate in cGMP production of FM101 antibody

Celgene announces positive data from its apremilast Phase IIb study for plaque-type psoriasis

Medicare power mobility remains a viable option for beneficiaries

Celebrex stops aspirin from doing its job effectively

Amgen receives worldwide rights to Array’s small-molecule glucokinase activator program

UCB offers tips for managing rheumatoid arthritis during festive season

NICE guidelines limit options for low cost osteoporosis drugs

Disabilities account for a quarter of U.S. adult health care costs

Hot Ideas World creates Eye-POD Eye Care Kit

Oconomowoc Memorial Hospital performs partial knee resurfacing surgery using MAKOplasty technology

Genentech and Biogen Idec report positive outcome from ocrelizumab-MTX combination study in RA

Nutritional supplements to strengthen immunity and improve periodontal health

Scientists develop new model of skin cancer based on Src kinases

Fulvestrant 500 mg reduces risk of disease progression in women with metastatic breast cancer

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Arthritis News and Research

Latest Arthritis News and Research

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Newsletters you may be interested in